Navigation Links
Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
Date:9/28/2007

PT. RICHMOND, Calif., Sept. 28 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs, today announced that Glenn A. Oclassen, President and Chief Executive Officer, is scheduled to present at the 2007 BIO Investor Forum at the Palace Hotel in San Francisco on Thursday, October 11, 2007 at 3:00 PM Pacific Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. The company's development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. Transcept's lead compound, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. TO-2060 is a novel, fixed-combination dose of olanzapine and ondansetron that is being evaluated for the treatment of dopamine associated psychiatric disorders (DAPD). TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder (AUD). For more information, please visit the Company's website at: http://www.transcept.com.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management ... begun to serve as its new executive director. Mr. Still was selected through a ... , “Bob, as he is known to our members, has been a part ...
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of ... medical professionals in the country to sit on the 2017 National Advisory Board for ... 2 years Dr. Harper helped propel the clinic from a small start-up to number ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... March 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: ... addressing cancer and other unmet medical needs, announced ... for Cancer Research annual meeting.  The first poster ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 ... poster to be presented on April 4 is ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... -- A recent study at Shriners Hospitals for Children – ... country dedicated to the treatment of pediatric burns and ... Surfacide Helios ® UV-C Disinfection System is ... not killed by the EVS (manual) cleaning process alone." ... Association,s 49th Annual Meeting in Boston ...
Breaking Medicine Technology: